tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperazine-1-carboxylate | 1327712-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperazine-1-carboxylate；tert-butyl 4-[4-(trifluoromethyl)benzoyl]piperazine-1-carboxylate
• CAS: 1327712-44-6
• 化学式: C₁₇H₂₁F₃N₂O₃
• 分子量: 358.361
• InChiKey: ZFTQRGZLMRSAAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperazine-1-carboxylate 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醚 为溶剂， 生成
  参考文献：
  名称：

  Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: Synthesis, SAR and biological evaluation

  摘要：

  Inhibitors of dipeptidyl peptidase-4 (DPP4) have been shown to be effective treatments for type 2 diabetes. Several series of beta-amino amide containing piperazine derivatives have been prepared and evaluated as a inhibitor of DPP4. Finally compound 5m was selected for further evaluation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.019
• 作为产物：
  描述：

  4-三氟甲基苯甲酸 在 氯化亚砜 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  一类厚朴酚衍生物及其制备方法与应用

  摘要：

  本发明公开了一类结构如式Ⅵ、Ⅴ所示的厚朴酚衍生物或其药学上可接受的盐，R选自#imgabs0#R’选自H、C1‑C4烷基。经试验表明，与厚朴酚相比，本发明所述的厚朴酚衍生物或其药学上可接受的盐的抗肝癌活性均有所提升，同时可以明显抑制肝癌细胞的迁移。本发明还公开了所述的厚朴酚衍生物或其药学上可接受的盐在制备治疗肝癌药物中的应用。#imgabs1#

  公开号：

  CN117820287A

文献信息

• [EN] QUINOXALINE DERIVATIVES AS GPR6 MODULATORS<br/>[FR] DÉRIVÉS DE QUINOXALINE EN TANT QUE MODULATEURS DU GPR6
  申请人：ENVOY THERAPEUTICS INC

  公开号：WO2014028479A1

  公开（公告）日：2014-02-20

  The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了式(I)化合物，该化合物是GPR6调节剂，因此可用于治疗可通过调节GPR6来治疗的疾病，特别是治疗帕金森病、左旋多巴诱导的舞蹈病、亨廷顿病、其他舞蹈病、运动不能、涉及纹状体功能障碍的运动障碍、精神分裂症和药物成瘾。还提供了含有此类化合物的药物组合物以及制备此类化合物的过程。
• QUINOXALINE DERIVATIVES AS GPR6 MODULATORS
  申请人：ENVOY THERAPEUTICS, INC.

  公开号：US20150232469A1

  公开（公告）日：2015-08-20

  The present invention provides compounds of Formula (I): that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供的化合物为式(I)的GPR6调节剂，因此可用于治疗可通过GPR6调节治疗的疾病，特别是治疗帕金森病、左多巴引起的运动障碍、亨廷顿病、其他运动障碍、无动力障碍以及涉及纹状体功能障碍的运动障碍、精神分裂症和药物成瘾。还提供了含有这种化合物的制药组合物以及制备这种化合物的过程。
• [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA<br/>[FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2022130352A1

  公开（公告）日：2022-06-23

  Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation of compounds of general formula (I) and intermediates thereof. Compounds of present invention can be useful in treating diseases such as hyperlipidemia and other disorders related to hyperlipidemia. Compounds of present invention also have a beneficial effect on lowering cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）化合物和中间体的过程。本发明的化合物可用于治疗高脂血症等与高脂血症相关的疾病。本发明的化合物还具有降低胆固醇的益处。
• Visible-light-induced dehydrogenative amidation of aldehydes enabled by iron salts
  作者：Han Gao、Lin Guo、Yining Zhu、Chao Yang、Wujiong Xia

  DOI：10.1039/d2cc06507j

  日期：——

  A direct dehydrogenative amidation reaction of aldehydes and amines under a visible light mediated ligand-to-metal charge transfer (LMCT) process was described. In this protocol, aldehyde substrates were activated by photoinduced hydrogen atom abstraction (HAA), generating acyl chloride intermediates followed by nucleophilic addition of amines. The synthetic method furnishes good functional group tolerance

  描述了在可见光介导的配体到金属电荷转移 (LMCT) 过程中醛和胺的直接脱氢酰胺化反应。在该协议中，醛底物被光诱导氢原子提取 (HAA) 激活，生成酰氯中间体，然后亲核加成胺。该合成方法对脂肪族和芳香族组分均具有良好的官能团耐受性和广泛的底物范围。
• Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
  作者：Hongyu Qin、Jian Zhang、Yilu Zhao、Lihui Zhang、Jinhong Feng、Lei Zhang

  DOI：10.3389/fphar.2022.1054616

  日期：——

  Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers.Methods: Aiming to the discovery of olaparib analogs for the treatment of cancer, structural modifications were performed based on the

  简介：聚（ADP-核糖）聚合酶 (PARP) 抑制剂的开发已在癌症治疗中得到广泛研究。奥拉帕尼是第一个获批的 PARP 抑制剂，显示出抑制 BRCA（乳腺癌相关）突变和 BRCA 未突变癌症的效力。方法：为了发现用于治疗癌症的奥拉帕尼类似物，进行了基于奥拉帕尼的脚手架。在第一系列中，羰基还原为CH2个导致 PARP1 抑制活性降低。在保留原始羰基的情况下，通过引入酰肼和芳香族氮芥基团，衍生出具有强效 PARP1 抑制活性的分子。合成的化合物在 PARP1 酶抑制筛选、基于癌细胞的抗增殖测定、细胞周期停滞和细胞凋亡研究中进行了评估。的抗癌效力体外抗增殖试验。与奥拉帕尼和苯丁酸氮芥相比，分子 C2 在抑制多种 BRCA 未突变细胞系方面也表现出显着的效力。进一步分析揭示了 C2 在诱导 G2/M 期细胞周期停滞和促进细胞凋亡方面的作用。讨论：总的来说，奥拉帕尼-苯丁酸氮芥杂化分子 (C2) 可用作进一步药物设计的先导化合物。